Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Learn about the latest prostate cancer clinical updates from ASCO 2025 in this 29-minute medical education video. Discover key findings from three major studies: AMPLITUDE showing how Niraparib combined with Abiraterone and ADT improves radiographic progression-free survival in HRR-mutated metastatic castration-sensitive prostate cancer, ARANOTE demonstrating that Darolutamide plus ADT is the first and only androgen receptor pathway inhibitor to improve health-related quality of life in mCSPC, and IRONMAN providing real-world evidence that PSA levels at 6 and 12 months serve as prognostic indicators when using ADT plus ARPI treatment combinations.
